drugset / Trial / NCT07157956
CVL006 Combination Therapy in Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with pemetrexed + carboplatin/SKB264/ DS-8201a/ Enfortumab Vedotin in patients with advanced solid tumors.
Timeline
- Start
- 2025-09-10
- Primary completion
- 2028-08-12
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVL006 | Monoclonal antibody | 10 mg/kg | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Enfortumab Vedotin | Other / unclassified | — | — |
| Background | Pemetrexed | Small molecule | — | — |
| Background | Sacituzumab Tirumotecan | Other / unclassified | — | — |
| Background | Trastuzumab deruxtecan | Monoclonal antibody | — | — |